Dose density during early induction has been demonstrated to be one of the prime determinants for treatment efficacy in acute myeloid leukemia (AML). The German AMLCooperative Group has therefore piloted a dose dense induction regimen S-HAM (sequential high-dose AraC and Mitoxantrone followed by pegfilgrastim) in which two induction cycles are applied over 11 -12 days instead of 25 -29 days as used in conventional double induction thereby increasing dose density two-fold. Of 172 de-novo AML patients (excluding acute promyelocytic leukemia) 61% reached a complete remission, 22% a complete remission with incomplete peripheral recovery, 7% had persistent leukemia, 10% succumbed to early death -resulting in an overall response rate of 83%. Kaplan Meier estimated survival at 2 years was 75% for the whole group [patients with unfavourable karyotypes 38%; patients with favourable karyotypes 69%; patients with intermediate karyotypes 75%] after S-HAM
INTRODUCTION
The overall prognosis of patients suffering from AML has steadily improved over the last three decades. Nowadays, complete remissions are achieved in 60 -70% of all patients with long-term disease free survival and potential cure in 25 -40% of cases. A more detailed analysis indicates that this progress has mainly been achieved in patients <60 years of age while in older patients little improvements have been obtained [1] [2] [3] [4] [5] .
When analyzing the approaches that underlie the progress in AML therapy two major developments appear essential: the intensification of therapy and the improvement of supportive care.
In the last few years increasing insights into the biology of AML have been gained. It has become clear that AML is a not a homogeneous disease but rather a group of different subtypes. These subtypes differ not only in their biology but also in their prognosis. Therefore genetic markers have become mandatory to discriminate prognostic subgroups and to adjust treatment according to distinct risk groups [6] [7] [8] [9] [10] [11] [12] . However the definition of distinct subgroups of AML is still mainly descriptive and the major challenge for clinicians and translational researchers remains how to treat these different subgroups most effectively and how to improve on their current outcome. Except for acute promyelocytic leukemia the better understanding of AML biology and the development of "targeted" therapies so far has not resulted in significant improvements in overall survival.
The standard induction therapy for AML is still a "3+7" type regimen comprising three days of Daunorubicin and seven days of standard-dose Cytosine Arabinoside (AraC) as continuous infusion 13, 14 . Based on cell biologic data, the German AML-CG modified the 3+7 regimen and established the TAD-9 regimen which is the combination of Thioguanine, AraC, and Daunorubicin 15 . The TAD-9 regimen resulted in a high CR rate and has been part of the induction strategies of the German AML-CG since 1979. For the dosing of Daunorubicin in particular an improvement in overall survival was demonstrated for full dosing as compared to reduced dosing in patients older than 60 years 16, 17 .
In an attempt to improve the long-term prognosis of patients with AML, the AML-CG introduced the concept of "double induction". This strategy is primarily focussed on patients < 60 years of age. It consists of two courses of chemotherapy irrespective of the degree of cytoreduction in the bone marrow after the first course with the second course starting on day 21 unless severe complications prohibit its application.
This strategy resulted in a significantly longer remission duration and overall survival as compared to standard induction 18 . In order to further improve on these results double induction with two courses of TAD 9 was compared to a first course of TAD 9 followed by high dose AraC (HD-AraC) plus Mitoxantrone (HAM) as second course. While no significant
For personal use only. on June 6, 2017. by guest www.bloodjournal.org From differences in outcome were observed for the overall group of patients a favourable effect of HAM was seen in the subgroup of high-risk patients as defined by unfavourable karyotype and/or elevated LDH level and/or residual day 16 bone marrow blasts with an OS at five years of 25% vs. 18% (p = 0.0118) 19 . The subsequently performed comparison of two courses of HAM (HAM/HAM) versus the TAD 9 /HAM sequence, however, showed no significant differences between HAM-HAM and TAD-HAM in terms of CR rate (71% vs. 65%), RFS at five years (35% vs. 29%), and OS at 5 years (32% vs. 30%) 20 . While the escalation of drug doses thus obviously has reached a limit, further intensification of therapy by shortening the time interval between induction cycles appeared as a promising new approach. This strategy was first evaluated in patients with relapsed and refractory AML. The S-HAM protocol was highly effective in patients with advanced disease (primary refractory or relapsed AML) with a CR rate of more than 50% but was complicated by a high early death rate from infections 23 , 24, 25 . Subsequent supportive therapy with G-CSF, however, reduced the duration of critical neutropenia from 40 to 36 days (p=0.008) and the ED rate from 30% to 21% (not significant) 26 . First results of dose dense therapy in first line therapy of de-novo AML were gained by a prospective randomised comparison of conventional versus dose dense therapy in children with AML. In the COG (Children Oncology Group) study 2891 dose dense therapy comprising Dexamethasone, Cytarabine, Thioguanine, Etoposide and Rubidomycin (DCTER) given on days 0-4 and 10-14 regardless of response was compared to the standard DCTER regimen given on days 0-4 and 14-18 or later, depending on response. Dose dense treatment resulted in a significantly longer disease-free and overall survival after 3 years of 55 % versus 37 % (p=0.0002) (DFS) and 52±6% versus 42±6 % (OS), respectively 27 . In adult patients a French study showed that a similar sequential approach (however not involving high-dose AraC) resulted in a surprisingly low hematological toxicity and a lower cumulative incidence of relapse as compared to conventional induction 28 .
These results prompted the AMLCG to assess the efficacy and feasibility of dosedense therapy with S-HAM in newly diagnosed de novo AML in a phase II study. Supportive therapy with pegfilgrastim was mandatory 29 . In addition, a three step escalation of treatment days was planned to obtain total doses of AraC and Mitoxantrone equivalent to the HAM-HAM arm of double induction therapy (Figure 1 ). 
PATIENTS AND METHODS

Patients and Entry Criteria
Adult patients (18 + years) with first diagnosis of de-novo AML (except acute promyelocytic leukemia APL) were eligible for the study. There was no upper age limit. Patients were ineligible in case of severe organ dysfunction not explained by leukemia.
Cytogenetic Subgroups
For exact characterization of leukaemia bone marrow samples underwent a standardised processing procedure including central sample registration, preparation, and evaluation by cytomorphology, cytochemistry, multiparameter immunophenotyping, cytogenetics, fluorescence in situ hybridization (FISH), and molecular genetics.
Favourable cytogenetics were defined as t(8;21) and inv (16 
Treatment Protocol
In the initial phase of the study S-HAM was given as previously used in advanced AML 23, 26 ).
This S-HAM basic (66%) regimen -which was identical in dose and schedule to the regimen used in the advanced studies -comprized AraC 3 g/m² as a 3 hours continuous infusion, bid 
Evaluation and Response Criteria
Response criteria were used as proposed by Cheson et al. 2003 30 . Patients dying within the first 65 days or while still cytopenic beyond this time were considered early deaths (ED) including those that had residual leukemia. Treatment related side effects were assessed by WHO criteria.
Data Description and Statistical Analysis
The aim of the present study was to test the feasibility of a dose-dense regimen in adult patients with de-novo AML. Therefore, overall toxicity and the early death rate were of particular relevance. Given an ED rate of 21,3% in 1238 patients with de novo AML treated within the AMLCG 1999 trial 20 and given the potential increase of efficacy achievable by dose-dense S-HAM induction therapy the present trial was to be stopped prematurely if an excessive death rate was observed (> 16% at 60 days; > 23% at 90 days).
In 
Study Conduct
The study was carried out in accordance with the modified Declaration of Helsinki. All patients gave their informed consent after having been informed about the purpose and the investigational nature of the trial. Before initiation the study received approval of the responsible institutional review board and the ethics committees of the participating institutions. The clinical study is an official study of the "Kompetenznetz Akute und
Chronische Leukämien" and is registered in the European Leukemia Trial Registry with the registration number LN_AMLINT_2004_230. 
Treatment Delivery:
Out of 172 patients recruited into the study 168 (= 98%) patients received their induction treatment as planned. Four patients did not receive the full treatment due to prohibitive toxicity within the first week of treatment (splenic rupture, pulmonary infiltrates, liver toxicity).
Three of these patients received only the first block of treatment -i.e. the equivalent of 1 cycle of HAM, 1 patient had also received 1 day of the 2 nd block when his treatment was stopped. These 4 patients are included into the following response analyses on an intention to treat basis.
After the feasibility of the S-HAM basis (66%) regimen had been demonstrated in the first 68 patients, the following patients were to receive the S-HAM escal (83%) regimen. However, when a significantly longer duration of neutropenia was observed after the S-HAM escal (83%)
regimen (see 3.3.) this regimen was restricted to patients < 60 years, whereas patients 60 + years went on to receive the S-HAM basis (66%) regimen in order to spare older patients from a prolonged duration of neutropenia. In total 113 patients received S-HAM basis (66%) and 59 patients S-HAM escal (83%).
After observing a 6 day prolongation of critical neutropenia by the addition of one more day of AraC and Mitoxantrone after the S-HAM esca (83%) regimen as compared to the S-HAM basis (66%) regimen it was decided that the dose-limiting toxicity was reached and a further escalation to S-HAM (100%) was not performed. There was no toxicity that was more frequent during S-HAM than during standard double induction.
When comparing the two evaluable dose levels of S-HAM serious infections were more frequent after S-HAM escal (83%) than after S-HAM basis (66%) -(54% versus 32%, p < 0,01) as was lung toxicity (34% versus 15%, p < 0,01).
Hematologic Toxicity:
The median time to leukocyte recovery (> 1000/µl) was 31 days after the start of treatment with S-HAM (figure 2a). When compared to de-novo AML patients treated with double induction within the AMLCG 1999 trial (median time to leukocyte recovery 46 days) the total duration of critical leukopenia was more than 2 weeks shorter after S-HAM (figure 2a). When comparing the two dose levels leukopenia after S-HAM escal (83%) was 6 days longer than after S-HAM basis (66%) -(figure 2b, 36 days versus 30 days, p < 0,01).
Response to Treatment:
A bone marrow aspirate was successfully performed 7 days after the completion of treatment in order to morphologically assess the early blast clearance (EBC) in 159 out of 172 patients.
The median percentage of residual blasts was 0% for the whole group. The EBC was higher after the S-HAM escal (83%) regimen as compared to S-HAM basis (66%) with 97% (range 0 - 
Overall Survival
The mean follow-up for the 172 patients is 13 months. The overall survival of the whole group is shown in figure 3a . Overall survival according to age, dose level and cytogenetic subgroup is shown in figures 3b -c, respectively.
Survival of patients < 60 years at 2 years after S-HAM was 67%, of patients 60 + years 45%.
In the AMLCG 1999 trial a 2 year survival of 55% and 30% was reached for patients < 60
and 60 + years respectively. No impact of CR i versus CR on overall survival was noted.
For personal use only. on June 6, 2017. by guest www.bloodjournal.org From
DISCUSSION
The current study indicates that the novel strategy of dose-dense intensive induction therapy for de-novo AML with the S-HAM regimen is feasible, is associated with a short period of critical neutropenia and appears highly active. Hence, an early death rate of only 10%, no increase in non-hematologic toxicity as compared to the preceding AMLCG study ´99, a median duration of critical neutropenia of only 31 days and an overall remission rate of 83% was observed in 172 consecutive patients entering this phase II trial.
The approach to investigate a dose-dense therapy for de novo AML emerged from several preceding findings: (1) Appropriate timing between cycles appears to be of crucial relevance for treatment related toxicities as well. Hence, the aforementioned intensively timed DCTER -DCTER regimen that was effective in children with AML was too toxic for adult patients when given with an interval of 6 -10 days 33 . A very similar experience was made by the AML-CG when two cycles of TAD-9 were given with a 7 days interval which resulted in an excessive rate of intestinal toxicity (unpublished data). Both experiences indicate that an around 7 day interval between treatment blocks leads to intolerable toxicity in adults. In accordance with our findings the ALFA 9000 study demonstrated that a 4 days interval between two intensively timed induction cycles in adult patients was associated with surprisingly low toxicity 28 .
The notion that a shortening of the time interval between treatment cycles might be associated with a good tolerability of therapy is also supported by experiences with the FLAMSA protocol in allogeneic transplantation. In this setting an intensive 4 day course of cytarabine, amsacrine and fludarabine is followed after an identical interval of 3 days by reduced intensity conditioning treatment with total body irradiation and cyclophosphamide with only very moderate non-hematological toxicities 34 .
The antileukemic efficacy of the S-HAM regimen was high with an ORR of 83% as compared to the historical control of 66% after double induction (AML-CG 1999, de-novo AML patients) and treatment failure (PL + ED) of 17% as compared to 34%. The difference in antileukemic efficacy was especially pronounced in the rate of early blast clearance (EBC), because in the S-HAM setting 91% of patients had less than 10% residual blast in the bone marrow on day 18 or 19 whereas after double induction this was only the case in 63% of patients on day 16.
With respect to EBC there was a significant difference between the two dose levels with the S-HAM escal (83%) being successful in 97% of patients as compared to 88% after the S-HAM basis (66%) regimen -indicating the substantial antileukemic efficacy of the S-HAM escal (83%) regimen. However since there was no superiority in overall survival for the higher dose level but a trend towards higher toxicity the S-HAM basis (66%) regimen was chosen as the candidate regimen for a future randomized comparison. As a result the overall survival following S-HAM also looked promising with a two year survival of 67% and 45% for patients < 60 and 60 + years respectively. This also compares favourably to the historical control of de-novo AML patients treated with double induction with a 55% and 30% overall survival at two years for patients < 60 and 60 + years respectively.
In conclusion the dose-dense intensive S-HAM regimen is a highly effective treatment regimen with a response rate of 83% and a low early death rate of 10% in the first 65 days which is most probably due to the short duration of critical neutropenia. In spite of these promising results a prospective randomized comparison of such a dose-reduced but intensely-timed therapy versus conventional double induction is required to prove the potential superiority of the new approach. This trial has been initiated within the next generation of the AML-CG studies (AML-CG 2008).
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